Brachytherapy Approach Using <sup>177</sup>Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model
Brachytherapy can provide sufficient doses to head and neck squamous cell carcinoma (HNSCC) with minimal damage to nearby normal tissues. In this study, the β<sup>−</sup>-emitter <sup>177</sup>Lu was conjugated to DTPA-polyethylene glycol (PEG) decorated gold nanostars (<s...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4d859694d2e94895830fab6fcac954dd |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Brachytherapy can provide sufficient doses to head and neck squamous cell carcinoma (HNSCC) with minimal damage to nearby normal tissues. In this study, the β<sup>−</sup>-emitter <sup>177</sup>Lu was conjugated to DTPA-polyethylene glycol (PEG) decorated gold nanostars (<sup>177</sup>Lu-DTPA-pAuNS) used in surface-enhanced Raman scattering and photothermal therapy (PTT). The accumulation and therapeutic efficacy of <sup>177</sup>Lu-DTPA-pAuNS were compared with those of <sup>177</sup>Lu-DTPA on an orthotopic HNSCC tumor model. The SPECT/CT imaging and biodistribution studies showed that <sup>177</sup>Lu-DTPA-pAuNS can be accumulated in the tumor up to 15 days, but <sup>177</sup>Lu-DTPA could not be detected at 24 h after injection. The tumor viability and growth were suppressed by injected <sup>177</sup>Lu-DTPA-pAuNS but not nonconjugated <sup>177</sup>Lu-DTPA, as evaluated by bioluminescent imaging. The radiation-absorbed dose of the normal organ was the highest in the liver (0.33 mSv/MBq) estimated in a 73 kg adult, but that of tumorsphere (0.5 g) was 3.55 mGy/MBq, while intravenous injection of <sup>177</sup>Lu-DTPA-pAuNS resulted in 1.97 mSv/MBq and 0.13 mGy/MBq for liver and tumorsphere, respectively. We also observed further enhancement of tumor-suppressive effects by a combination of <sup>177</sup>Lu-DTPA-pAuNS and PTT compared to <sup>177</sup>Lu-DTPA-pAuNS alone. In conclusion, <sup>1</sup><sup>77</sup>Lu-DTPA-pAuNS may be considered as a potential radiopharmaceutical agent for HNSCC brachytherapy. |
|---|